FindTrial
Sign In

Onartuzumab

DRUG9 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche, M.D. Anderson Cancer Center

Conditions

Breast CancerCarcinoma, HepatocellularGastric CancerGlioblastomaLung CancerNeoplasmsNon-Squamous Non-Small Cell Lung CancerSolid Tumor

Phase 1

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
CompletedNCT01897038
Hoffmann-La RocheCarcinoma, Hepatocellular
Start: 2013-09-30End: 2015-03-31Updated: 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
WithdrawnNCT01974258
Hoffmann-La RocheNeoplasms
Start: 2014-02-28End: 2014-07-31Updated: 2016-11-02
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
WithdrawnNCT02044601
M.D. Anderson Cancer CenterLung Cancer
Start: 2014-06-30Updated: 2014-04-24

Phase 2

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
CompletedNCT01186991
Genentech, Inc.Breast Cancer
Start: 2011-03-31End: 2016-03-31Updated: 2017-01-20
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
CompletedNCT01519804
Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer
Start: 2012-04-30End: 2015-09-30Updated: 2016-09-02
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
CompletedNCT01632228
Hoffmann-La RocheGlioblastoma
Start: 2012-06-29End: 2016-01-21Updated: 2018-02-05

Phase 3

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
CompletedNCT01662869
Hoffmann-La RocheGastric Cancer
Start: 2012-11-30End: 2015-12-31Updated: 2016-11-02
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
CompletedNCT01887886
Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer
Start: 2013-12-31End: 2015-02-28Updated: 2016-11-02
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
CompletedNCT02488330
Hoffmann-La RocheSolid Tumor
Start: 2015-08-27End: 2018-06-29Updated: 2019-07-23

Related Papers

Dissecting gastric cancer biology and how and when to use immunotherapy
Annals of Oncology2018-10-01
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
JAMA Oncology2016-12-05292 citations
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
2015-07-2256 citations
METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).
Journal of Clinical Oncology2015-05-20102 citations
Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.
Journal of Clinical Oncology2015-05-2037 citations
Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).
Journal of Clinical Oncology2015-01-2041 citations
False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.
Journal of Clinical Oncology2015-01-2015 citations